Consolidating the Foundation in Small Molecules, Setting Sail for the Future of Oligonucleotides

In an era of vibrant pharmaceutical innovation, Lianhe Aigen maintains an open perspective to navigate industry shifts and embraces emerging opportunities with an innovative spirit. As a trusted partner in the small-molecule CDMO space, we continue to strengthen our core business while proactively expanding into new frontiers—including oligonucleotide therapeutics—to build a more diversified service capability matrix.

A Solid Foundation: Deep Expertise in Small-Molecule CDMO

In the small-molecule field, we have established comprehensive technology platforms and a robust quality system. Leveraging mature process development, rigorous quality control, and stable scale-up production capacity, we have successfully advanced numerous innovative drug programs from lab to market. This deep expertise and extensive project experience have not only earned long-term client trust but also laid a strong groundwork for our expansion into emerging businesses.

Strategic Expansion: A Milestone in Oligonucleotide CDMO

With the advent of precision medicine, oligonucleotide therapeutics are emerging as a transformative treatment modality with immense potential. Keenly attuned to industry trends, we began building our oligonucleotide CDMO technology platform several years ago. Today, this business has reached a significant milestone—we are now moving forward with the planning and construction of a dedicated manufacturing facility designed to international standards. This state-of-the-art site will deliver full-phase service capabilities, from clinical sample supply to commercial production, offering clients reliable and scalable capacity assurance.

Co-Creating the Future: Partnering with Innovators

From classic small-molecule drugs to cutting-edge oligonucleotide therapies, we stand alongside pharmaceutical innovators every step of the way. In this new phase of growth, we will continue to uphold our philosophy of “Quality First, Customer Foremost,” leveraging stronger technology platforms, more specialized service teams, and more dependable capacity to help bring innovative medicines to patients sooner.